It looks like a new respirator developed in the Netherlands will be launched on the market next year. The equipment recently received CE approval and clinical trials will start soon.
Breathing under control
The so-called Enove device, a product of the Eindhoven-based company Ventinova, is different from other respirators. Namely, it actively supports exhalation by sucking gases from the lungs. It thus provides control during both inhalation and exhalation. "We have a large network of key opinion leaders in the field of artificial ventilation who are convinced about this ventilation method. I believe Evone sets a new standard in this and offers substantial benefits in different areas of surgery," said Dirk van Asseldonk, founder and CEO of Ventinova in a press release.
Evone achieves full breathing control in combination with an ultra-thin tube; exhalation is assisted by suction. This ultra-thin tube, called Tribute®, has an outer diameter of barely 4.4 mm, unlike the 10 mm of more conventional tubes. As it were, it allows surgeons and anaesthetists more space to do in operations. In addition, the doctor's vision is increased and improved.
Reducing lung complications
Studies prior to the device's development showed that ventilation method from Enova may lead to a reduction in lung complications resulting from a patient's regular artificial ventilation method. Combined with the Tribute tube, the new ventilator is able to slow exhalation, reducing sudden pressure changes in the lungs. "Ventinova's new method offers several new treatment options for ENT surgeons and anaesthetists and promises better ventilation of patients in the operating theatre," says Dietmar Enk, creator of Evone's working principle and professor of Anaesthesiology.
In the Netherlands, Ventinova will do direct sales, this will eventually also happen in Belgium and Germany. The company eventually wants to establish an international distributor network.
The first clinical studies at several European hospitals will start in the coming months. The initial focus will be on ventilation of different groups of patients under full anaesthesia in the OR.
Ventinova began as a spinoff from TU Eindhoven. The founders initially developed the Ventrain, a purely pneumatic small device for the temporary ventilation of patients with an acute respiratory problem, such as choking or allergic reaction. Holland Venture and the Brabant Development Company invested 2 million euros in the startup at the time.
By: Kelly Bakker
Source + photo: Ventinova
